EconPapers    
Economics at your fingertips  
 

Research funding and price negotiation for new drugs

Francesca Barigozzi and Izabela Jelovac

Working Papers from HAL

Abstract: Pharmaceutical innovations result from the successful achievement of basic research, produced by an upstream lab, and applied research, produced by a downstream lab. We focus on the negotiation process to finance basic research by setting public and private grants and to agree on the final price of a new drug. We show that exclusive funding of basic research is desirable. To increase consumers' surplus and reduce negotiated prices for new drugs, basic and applied research should be integrated if the lab producing applied research has a relatively large bargaining power. When instead the health authority has the larger bargaining power, integration with the producer of basic research increases negotiated prices for new drugs and should be avoided, unless the gain in bargaining power after the integration is extremely high. Abstract. Pharmaceutical innovations result from the successful achievement of basic research, produced by an upstream lab, and applied research, produced by a downstream lab. We focus on the negotiation process to finance basic research by setting public and private grants and to agree on the final price of a new drug. We show that exclusive funding of basic research is desirable. To increase consumers' surplus and reduce negotiated prices for new drugs, basic and applied research should be integrated if the lab producing applied research has a relatively large bargaining power. When instead the health authority has the larger bargaining power, integration with the producer of basic research increases negotiated prices for new drugs and should be avoided, unless the gain in bargaining power after the integration is extremely high.

Keywords: Pharmaceutical innovation; drug prices; negotiation; basic research; applied research (search for similar items in EconPapers)
Date: 2019-01-21
New Economics Papers: this item is included in nep-hea, nep-ino and nep-mic
Note: View the original document on HAL open archive server: https://shs.hal.science/halshs-01987643v1
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://shs.hal.science/halshs-01987643v1/document (application/pdf)

Related works:
Journal Article: Research funding and price negotiation for new drugs (2020) Downloads
Working Paper: Research funding and price negotiation for new drugs (2020)
Working Paper: Research funding and price negotiation for new drugs (2019) Downloads
Working Paper: Research funding and price negotiation for new drugs (2019)
Working Paper: Research funding and price negotiation for new drugs (2019)
Working Paper: Research funding and price negotiation for new drugs (2019)
Working Paper: Research funding and price negotiation for new drugs (2019)
Working Paper: Research funding and price negotiation for new drugs (2019)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:wpaper:halshs-01987643

Access Statistics for this paper

More papers in Working Papers from HAL
Bibliographic data for series maintained by CCSD ().

 
Page updated 2025-03-22
Handle: RePEc:hal:wpaper:halshs-01987643